← 產業報告目錄
AI in Respiratory Diseases Industry Research Report 2026
出版商 APO Research產業別 Software & IT Services出版日期 2026-07-04頁數 133報告編號 APO-4830c1b701
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global AI in Respiratory Diseases market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI in Respiratory Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI in Respiratory Diseases market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI in Respiratory Diseases market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI in Respiratory Diseases include ArtiQ, Philips Healthcare, GE Healthcare, Siemens Healthineers, Swaasa AI, THIRONA, DeepMind Health, Verily and VIDA Diagnostics Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global AI in Respiratory Diseases market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI in Respiratory Diseases.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI in Respiratory Diseases Market by Company
ArtiQ
Philips Healthcare
GE Healthcare
Siemens Healthineers
Swaasa AI
THIRONA
DeepMind Health
Verily
VIDA Diagnostics Inc
Icometrix
Infervision
PneumoWave
Respiray
Dectrocel Healthcare
Zynnon
AI in Respiratory Diseases Segment by Type
Pulmonary Infection
MRI
CT Scan
AI in Respiratory Diseases Segment by Application
Hospital
Diagnostic Centers
Ambulatory Surgical Centers
Others
AI in Respiratory Diseases Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI in Respiratory Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI in Respiratory Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI in Respiratory Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI in Respiratory Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 AI in Respiratory Diseases by Type
2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
2.2.2 Pulmonary Infection
2.2.3 MRI
2.2.4 CT Scan
2.3 AI in Respiratory Diseases by Application
2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.3.2 Hospital
2.3.3 Diagnostic Centers
2.3.4 Ambulatory Surgical Centers
2.3.5 Others
2.4 Assumptions and Limitations
3 AI in Respiratory Diseases Breakdown Data by Type
3.1 Global AI in Respiratory Diseases Historic Market Size by Type (2021-2026)
3.2 Global AI in Respiratory Diseases Forecasted Market Size by Type (2027-2032)
4 AI in Respiratory Diseases Breakdown Data by Application
4.1 Global AI in Respiratory Diseases Historic Market Size by Application (2021-2026)
4.2 Global AI in Respiratory Diseases Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
5.1 Global AI in Respiratory Diseases Market Perspective (2021-2032)
5.2 Global AI in Respiratory Diseases Growth Trends by Region
5.2.1 Global AI in Respiratory Diseases Market Size by Region: 2021 VS 2025 VS 2032
5.2.2 AI in Respiratory Diseases Historic Market Size by Region (2021-2026)
5.2.3 AI in Respiratory Diseases Forecasted Market Size by Region (2027-2032)
5.3 AI in Respiratory Diseases Market Dynamics
5.3.1 AI in Respiratory Diseases Industry Trends
5.3.2 AI in Respiratory Diseases Market Drivers
5.3.3 AI in Respiratory Diseases Market Challenges
5.3.4 AI in Respiratory Diseases Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top AI in Respiratory Diseases Players by Revenue
6.1.1 Global Top AI in Respiratory Diseases Players by Revenue (2021-2026)
6.1.2 Global AI in Respiratory Diseases Revenue Market Share by Players (2021-2026)
6.2 Global AI in Respiratory Diseases Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of AI in Respiratory Diseases Head Office and Area Served
6.4 Global AI in Respiratory Diseases Players, Product Type & Application
6.5 Global AI in Respiratory Diseases Manufacturers Established Date
6.6 Global AI in Respiratory Diseases Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America AI in Respiratory Diseases Market Size (2021-2032)
7.2 North America AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
7.3 North America AI in Respiratory Diseases Market Size by Country (2021-2026)
7.4 North America AI in Respiratory Diseases Market Size by Country (2027-2032)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe AI in Respiratory Diseases Market Size (2021-2032)
8.2 Europe AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
8.3 Europe AI in Respiratory Diseases Market Size by Country (2021-2026)
8.4 Europe AI in Respiratory Diseases Market Size by Country (2027-2032)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific AI in Respiratory Diseases Market Size (2021-2032)
9.2 Asia-Pacific AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
9.3 Asia-Pacific AI in Respiratory Diseases Market Size by Country (2021-2026)
9.4 Asia-Pacific AI in Respiratory Diseases Market Size by Country (2027-2032)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America AI in Respiratory Diseases Market Size (2021-2032)
10.2 South America AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
10.3 South America AI in Respiratory Diseases Market Size by Country (2021-2026)
10.4 South America AI in Respiratory Diseases Market Size by Country (2027-2032)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa AI in Respiratory Diseases Market Size (2021-2032)
11.2 Middle East & Africa AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
11.3 Middle East & Africa AI in Respiratory Diseases Market Size by Country (2021-2026)
11.4 Middle East & Africa AI in Respiratory Diseases Market Size by Country (2027-2032)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 ArtiQ
12.1.1 ArtiQ Company Information
12.1.2 ArtiQ Business Overview
12.1.3 ArtiQ Revenue in AI in Respiratory Diseases Business (2021-2026)
12.1.4 ArtiQ AI in Respiratory Diseases Product Portfolio
12.1.5 ArtiQ Recent Developments
12.2 Philips Healthcare
12.2.1 Philips Healthcare Company Information
12.2.2 Philips Healthcare Business Overview
12.2.3 Philips Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026)
12.2.4 Philips Healthcare AI in Respiratory Diseases Product Portfolio
12.2.5 Philips Healthcare Recent Developments
12.3 GE Healthcare
12.3.1 GE Healthcare Company Information
12.3.2 GE Healthcare Business Overview
12.3.3 GE Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026)
12.3.4 GE Healthcare AI in Respiratory Diseases Product Portfolio
12.3.5 GE Healthcare Recent Developments
12.4 Siemens Healthineers
12.4.1 Siemens Healthineers Company Information
12.4.2 Siemens Healthineers Business Overview
12.4.3 Siemens Healthineers Revenue in AI in Respiratory Diseases Business (2021-2026)
12.4.4 Siemens Healthineers AI in Respiratory Diseases Product Portfolio
12.4.5 Siemens Healthineers Recent Developments
12.5 Swaasa AI
12.5.1 Swaasa AI Company Information
12.5.2 Swaasa AI Business Overview
12.5.3 Swaasa AI Revenue in AI in Respiratory Diseases Business (2021-2026)
12.5.4 Swaasa AI AI in Respiratory Diseases Product Portfolio
12.5.5 Swaasa AI Recent Developments
12.6 THIRONA
12.6.1 THIRONA Company Information
12.6.2 THIRONA Business Overview
12.6.3 THIRONA Revenue in AI in Respiratory Diseases Business (2021-2026)
12.6.4 THIRONA AI in Respiratory Diseases Product Portfolio
12.6.5 THIRONA Recent Developments
12.7 DeepMind Health
12.7.1 DeepMind Health Company Information
12.7.2 DeepMind Health Business Overview
12.7.3 DeepMind Health Revenue in AI in Respiratory Diseases Business (2021-2026)
12.7.4 DeepMind Health AI in Respiratory Diseases Product Portfolio
12.7.5 DeepMind Health Recent Developments
12.8 Verily
12.8.1 Verily Company Information
12.8.2 Verily Business Overview
12.8.3 Verily Revenue in AI in Respiratory Diseases Business (2021-2026)
12.8.4 Verily AI in Respiratory Diseases Product Portfolio
12.8.5 Verily Recent Developments
12.9 VIDA Diagnostics Inc
12.9.1 VIDA Diagnostics Inc Company Information
12.9.2 VIDA Diagnostics Inc Business Overview
12.9.3 VIDA Diagnostics Inc Revenue in AI in Respiratory Diseases Business (2021-2026)
12.9.4 VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio
12.9.5 VIDA Diagnostics Inc Recent Developments
12.10 Icometrix
12.10.1 Icometrix Company Information
12.10.2 Icometrix Business Overview
12.10.3 Icometrix Revenue in AI in Respiratory Diseases Business (2021-2026)
12.10.4 Icometrix AI in Respiratory Diseases Product Portfolio
12.10.5 Icometrix Recent Developments
12.11 Infervision
12.11.1 Infervision Company Information
12.11.2 Infervision Business Overview
12.11.3 Infervision Revenue in AI in Respiratory Diseases Business (2021-2026)
12.11.4 Infervision AI in Respiratory Diseases Product Portfolio
12.11.5 Infervision Recent Developments
12.12 PneumoWave
12.12.1 PneumoWave Company Information
12.12.2 PneumoWave Business Overview
12.12.3 PneumoWave Revenue in AI in Respiratory Diseases Business (2021-2026)
12.12.4 PneumoWave AI in Respiratory Diseases Product Portfolio
12.12.5 PneumoWave Recent Developments
12.13 Respiray
12.13.1 Respiray Company Information
12.13.2 Respiray Business Overview
12.13.3 Respiray Revenue in AI in Respiratory Diseases Business (2021-2026)
12.13.4 Respiray AI in Respiratory Diseases Product Portfolio
12.13.5 Respiray Recent Developments
12.14 Dectrocel Healthcare
12.14.1 Dectrocel Healthcare Company Information
12.14.2 Dectrocel Healthcare Business Overview
12.14.3 Dectrocel Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026)
12.14.4 Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio
12.14.5 Dectrocel Healthcare Recent Developments
12.15 Zynnon
12.15.1 Zynnon Company Information
12.15.2 Zynnon Business Overview
12.15.3 Zynnon Revenue in AI in Respiratory Diseases Business (2021-2026)
12.15.4 Zynnon AI in Respiratory Diseases Product Portfolio
12.15.5 Zynnon Recent Developments
13 Report Conclusion
14 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global AI in Respiratory Diseases Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global AI in Respiratory Diseases Revenue Market Share by Type (2021-2026)
Table 7. Global AI in Respiratory Diseases Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global AI in Respiratory Diseases Revenue Market Share by Type (2027-2032)
Table 9. Global AI in Respiratory Diseases Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global AI in Respiratory Diseases Revenue Market Share by Application (2021-2026)
Table 11. Global AI in Respiratory Diseases Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global AI in Respiratory Diseases Revenue Market Share by Application (2027-2032)
Table 13. Global AI in Respiratory Diseases Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global AI in Respiratory Diseases Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global AI in Respiratory Diseases Market Share by Region (2021-2026)
Table 16. Global AI in Respiratory Diseases Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global AI in Respiratory Diseases Market Share by Region (2027-2032)
Table 18. AI in Respiratory Diseases Industry Trends
Table 19. AI in Respiratory Diseases Industry Drivers
Table 20. AI in Respiratory Diseases Industry Opportunities and Challenges
Table 21. AI in Respiratory Diseases Market Restraints
Table 22. Global Top AI in Respiratory Diseases Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global AI in Respiratory Diseases Revenue Market Share by Players (2021-2026)
Table 24. Global AI in Respiratory Diseases Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of AI in Respiratory Diseases, Headquarters and Area Served
Table 26. Global AI in Respiratory Diseases Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global AI in Respiratory Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America AI in Respiratory Diseases Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America AI in Respiratory Diseases Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe AI in Respiratory Diseases Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe AI in Respiratory Diseases Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific AI in Respiratory Diseases Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific AI in Respiratory Diseases Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America AI in Respiratory Diseases Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America AI in Respiratory Diseases Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa AI in Respiratory Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa AI in Respiratory Diseases Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa AI in Respiratory Diseases Market Size by Country (2027-2032) & (US$ Million)
Table 45. ArtiQ Company Information
Table 46. ArtiQ Business Overview
Table 47. ArtiQ Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 48. ArtiQ AI in Respiratory Diseases Product Portfolio
Table 49. ArtiQ Recent Developments
Table 50. Philips Healthcare Company Information
Table 51. Philips Healthcare Business Overview
Table 52. Philips Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 53. Philips Healthcare AI in Respiratory Diseases Product Portfolio
Table 54. Philips Healthcare Recent Developments
Table 55. GE Healthcare Company Information
Table 56. GE Healthcare Business Overview
Table 57. GE Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 58. GE Healthcare AI in Respiratory Diseases Product Portfolio
Table 59. GE Healthcare Recent Developments
Table 60. Siemens Healthineers Company Information
Table 61. Siemens Healthineers Business Overview
Table 62. Siemens Healthineers Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 63. Siemens Healthineers AI in Respiratory Diseases Product Portfolio
Table 64. Siemens Healthineers Recent Developments
Table 65. Swaasa AI Company Information
Table 66. Swaasa AI Business Overview
Table 67. Swaasa AI Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 68. Swaasa AI AI in Respiratory Diseases Product Portfolio
Table 69. Swaasa AI Recent Developments
Table 70. THIRONA Company Information
Table 71. THIRONA Business Overview
Table 72. THIRONA Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 73. THIRONA AI in Respiratory Diseases Product Portfolio
Table 74. THIRONA Recent Developments
Table 75. DeepMind Health Company Information
Table 76. DeepMind Health Business Overview
Table 77. DeepMind Health Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 78. DeepMind Health AI in Respiratory Diseases Product Portfolio
Table 79. DeepMind Health Recent Developments
Table 80. Verily Company Information
Table 81. Verily Business Overview
Table 82. Verily Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 83. Verily AI in Respiratory Diseases Product Portfolio
Table 84. Verily Recent Developments
Table 85. VIDA Diagnostics Inc Company Information
Table 86. VIDA Diagnostics Inc Business Overview
Table 87. VIDA Diagnostics Inc Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 88. VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio
Table 89. VIDA Diagnostics Inc Recent Developments
Table 90. Icometrix Company Information
Table 91. Icometrix Business Overview
Table 92. Icometrix Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 93. Icometrix AI in Respiratory Diseases Product Portfolio
Table 94. Icometrix Recent Developments
Table 95. Infervision Company Information
Table 96. Infervision Business Overview
Table 97. Infervision Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 98. Infervision AI in Respiratory Diseases Product Portfolio
Table 99. Infervision Recent Developments
Table 100. PneumoWave Company Information
Table 101. PneumoWave Business Overview
Table 102. PneumoWave Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 103. PneumoWave AI in Respiratory Diseases Product Portfolio
Table 104. PneumoWave Recent Developments
Table 105. Respiray Company Information
Table 106. Respiray Business Overview
Table 107. Respiray Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 108. Respiray AI in Respiratory Diseases Product Portfolio
Table 109. Respiray Recent Developments
Table 110. Dectrocel Healthcare Company Information
Table 111. Dectrocel Healthcare Business Overview
Table 112. Dectrocel Healthcare Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 113. Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio
Table 114. Dectrocel Healthcare Recent Developments
Table 115. Zynnon Company Information
Table 116. Zynnon Business Overview
Table 117. Zynnon Revenue in AI in Respiratory Diseases Business (2021-2026) & (US$ Million)
Table 118. Zynnon AI in Respiratory Diseases Product Portfolio
Table 119. Zynnon Recent Developments
Table 120. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. AI in Respiratory Diseases Product Image
Figure 5. Global AI in Respiratory Diseases Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global AI in Respiratory Diseases Market Share by Type: 2025 VS 2032
Figure 7. Pulmonary Infection Product
Figure 8. MRI Product
Figure 9. CT Scan Product
Figure 10. Global AI in Respiratory Diseases Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global AI in Respiratory Diseases Market Share by Application: 2025 VS 2032
Figure 12. Hospital Product
Figure 13. Diagnostic Centers Product
Figure 14. Ambulatory Surgical Centers Product
Figure 15. Others Product
Figure 16. Global AI in Respiratory Diseases Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 17. Global AI in Respiratory Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 18. Global AI in Respiratory Diseases Market Share by Region: 2025 VS 2032
Figure 19. Global AI in Respiratory Diseases Market Share by Players in 2025
Figure 20. Global AI in Respiratory Diseases Manufacturers Established Date
Figure 21. Global Top 5 and 10 AI in Respiratory Diseases Players Market Share by Revenue in 2025
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 23. North America AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 24. North America AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 25. United States AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 26. Canada AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Mexico AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 28. Europe AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. Europe AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 30. Germany AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. France AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. U.K. AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Italy AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Spain AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Russia AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Netherlands AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Nordic Countries AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Asia-Pacific AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Asia-Pacific AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 40. China AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. Japan AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. South Korea AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. India AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. India AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 45. Australia AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. China Taiwan AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. Southeast Asia AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. South America AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. South America AI in Respiratory Diseases Market Share by Country (2021-2032)
Figure 50. Brazil AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Argentina AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Chile AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Colombia AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 54. Peru AI in Respiratory Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 55. ArtiQ Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 56. Philips Healthcare Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 57. GE Healthcare Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 58. Siemens Healthineers Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 59. Swaasa AI Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 60. THIRONA Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 61. DeepMind Health Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 62. Verily Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 63. VIDA Diagnostics Inc Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 64. Icometrix Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 65. Infervision Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 66. PneumoWave Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 67. Respiray Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 68. Dectrocel Healthcare Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
Figure 69. Zynnon Revenue Growth Rate in AI in Respiratory Diseases Business (2021-2026)
提及公司
ArtiQPhilips HealthcareGE HealthcareSiemens HealthineersSwaasa AITHIRONADeepMind HealthVerilyVIDA Diagnostics IncIcometrixInfervisionPneumoWaveRespirayDectrocel HealthcareZynnon
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們